Physician profile
Sarah E Wilson
NPI 1144645441
$6,093.41
in general payments reported to CMS, 2019-2025
27 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,170 · 2022: $1,228 · 2023: $1,128 · 2024: $1,353 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,695.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,305.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,242.48 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $960.15 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $415.62 | 2021-2025 | Linzess |
| Intercept Pharmaceuticals, INC. | $255.79 | 2021-2025 | Ocaliva |
| Pfizer INC. | $231.31 | 2021-2025 | |
| Madrigal Pharmaceuticals | $214.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $203.33 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $186.33 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $179.91 | 2022-2025 | Entyvio |
| Qol Medical, LLC | $158.85 | 2021-2024 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $100.57 | 2021-2022 | |
| Ardelyx, INC. | $100.30 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $87.82 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $77.29 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $70.48 | 2024-2025 | Zenpep |
| Celgene Corporation | $66.31 | 2021-2022 | |
| Evoke Pharma, INC. | $56.90 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $31.63 | 2023 | |
| Ferring Pharmaceuticals INC. | $29.21 | 2023 | Rebyota |
| Medtronic, INC. | $22.12 | 2023 | Pillcam |
| Lilly USA, LLC | $18.21 | 2025 | Omvoh |
| Axonics, INC. | $17.76 | 2021 | |
| Echosens North America, INC. | $16.62 | 2024 | Fibroscan |
| Ambu INC. | $15.70 | 2021 | |
| Sumitomo Pharma America, INC. | $15.15 | 2023 | Gemtesa |
| Braintree Laboratories, INC. | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.